Author

Tomoko Ichihara

Institution: Takamatsu Red Cross Hospital

Observed institutions: Taisho Pharmaceutical (Japan), Takamatsu Red Cross Hospital

OpenAlex ID: A5113720163

Mechanism of action of aragusterol a (YTA0040), a potent anti-tumor marine steroid targeting the G1 phase of the cell cycle

2000 · Kazuya Fukuoka, Takehiro Yamagishi, et al. · International Journal of Cancer · 30

In vivo activity on murine tumors of a novel antitumor compound, N-?-dimethylaminoethyl 9-carboxy-5-hydroxy-10-methoxybenzo[a]phenazine-6-carboxamide sodium salt (NC-190)

1989 · Shiro Nakaike, Takehiro Yamagishi, et al. · Cancer Chemotherapy and Pharmacology · 15

Novel water-soluble analogues retaining potent antitumor activity of RA-VII, a cyclic hexapeptide from Rubia plants

1997 · Yukio Hitotsuyanagi, Yoshiaki Anazawa, et al. · Bioorganic & Medicinal Chemistry Letters · 9

Establishment and characterization of a mouse FM3A cell mutant resistant to topoisomerase II-inhibitor NC-190

2002 · Kazunori Samata, Takehiro Yamagishi, et al. · Cancer Chemotherapy and Pharmacology · 8

Overcoming of multidrug resistance by VA-033, a novel derivative of apovincaminic acid ester

1997 · Kayoko Nanaumi, Katsuharu Tsuchida, et al. · European Journal of Pharmacology · 3

A case of glomerular phospholipase A2 receptor-positive idiopathic membranous nephropathy without deposition of complements

2016 · Keisuke Fujioka, Maki Shimizu, et al. · Japanese journal of pediatric nephrology

Works count: 6

Citation count: 65

H-index: 4

I10-index: 2